echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Guilin Sanjinsun Company BC006 monoclonal antibody injection obtained clinical trial approval

    Guilin Sanjinsun Company BC006 monoclonal antibody injection obtained clinical trial approval

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 21, Guilin Sanjin issued an announcement stating that, recently, its holding company, Baochuan Biomedical Technology (Shanghai) Co.


    BC006 monoclonal antibody injection is a humanized IgG1 monoclonal antibody against macrophage colony stimulating factor 1 receptor (CSF-1R, Colony Stimulating Factor 1 Receptor), which specifically targets the surface of monocyte-macrophage mesangial cells CSF-1R inhibits its dimerization and blocks the activation of downstream intracellular signaling pathways, thereby reducing the number of immunosuppressive M2-like macrophages in the tumor microenvironment, restoring the function of macrophages, and producing anti-tumor effects.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.